Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., listed under ticker DECA, is a clinical-stage biopharmaceutical company that reached the public markets through a business combination with Decathlon Alpha IV, a healthcare-focused special purpose acquisition company that completed its IPO in 2021 under Decathlon Alpha IV Sponsor, LLC. The combined entity is developing novel therapeutics for spinal and neuropathic pain, with a pipeline concentrated on epidural drug delivery and non-opioid pain management. Semnur filed its Form 10-Q quarterly report on August 15, 2025, reflecting its continued operations as a post-merger public company in the specialty pharmaceuticals sector. Sign up on SpacDesk for full transaction records, filing timelines, and SPAC deal analytics.